Logo

Pfizer and Astellas Amends Clinical Research Protocols of Xtandi for 2 Phase III to treat Hormone-Sensitive Prostate Cancer (HSPC)

Share this

Pfizer and Astellas Amends Clinical Research Protocols of Xtandi for 2 Phase III to treat Hormone-Sensitive Prostate Cancer (HSPC)

Shots:

  • The amendments accelerate timelines for the anticipated primary completion dates of both trials
  • ARCHES and EMBARK Phase III trials have been amended its primary completion time from April 2020 to late 2018 and Mar-2021 to mid-2020 respectively
  • In Oct 2009- Pfizer (Medivation) and Astellas entered into a global agreement to jointly develop and commercialize Xtandi (enzalutamide)

            Ref: Pfizer | Image:  Pfizer

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions